BackChromocell Therapeutics Overview

Chromocell Therapeutics Receivables

Chromocell Therapeutics's receivables is $12M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$11.70M

Peer trimmed avg / median

Loading

Chromocell Therapeutics Receivables History

Loading

Chromocell Therapeutics vs. peers: Receivables Comparison

Loading

Chromocell Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Chromocell Therapeutics (CHRO) FAQ

As of the most recent data (March 2026), CHRO shows a receivables of $12M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CHRO's receivables is now $12M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Chromocell Therapeutics is outperforming or lagging.

Tracking CHRO's receivables over time shows whether Chromocell Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $12M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Chromocell Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $12M) with ownership activity and broader fundamentals.